je.st
news
A risky biotech stock's rise and fall
2015-03-14 00:32:54| Biotech - Topix.net
Biotech firm Neuralstem's stock sank by 37% Thursday, to $2.37 a share, after it reported disappointing results from a clinical trial. In January 2014, a 41-year-old mother named April Moundzouris who had been diagnosed with amyotrophic lateral sclerosis, or Lou Gehrig's disease, blogged that she was responding well to treatment in a clinical trial.
Tags: fall
rise
stocks
biotech
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||